-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Minimally Invasive Xintong-B (02160.HK) issued an announcement. Recently, the results of a one-year follow-up study on the early feasibility study of AltaValveTM transcatheter mitral valve replacement (TMVR) medical device (AltaValveTM) independently developed by 4C Medical Technologies, Inc. (4C Medical), a group affiliate, were officially announced.

Zhitongcaijing·12/30/2025 14:57:02
Listen to the news
Zhitong Finance App News, Minimally Invasive Xintong-B (02160.HK) issued an announcement. Recently, the results of a one-year follow-up study on the early feasibility study of AltaValveTM transcatheter mitral valve replacement (TMVR) medical device (AltaValveTM) independently developed by 4C Medical Technologies, Inc. (4C Medical), a group affiliate, were officially announced.